Early research (Phase 1)WithdrawnNCT04043845
What this trial is testing
ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies
Who this might be right for
Chronic Lymphocytic LeukemiaWaldenstrom MacroglobulinemiaMantle Cell Lymphoma+1 more
Dana-Farber Cancer Institute